Akebia Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders' Equity (Deficit

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Equity (Deficit)
(dollars in thousands) · Shares · Amount
Balance at December 31, 2024	224,848,992		$2	$1,629,167	$6	$(1,678,360)	$(49,185)
Issuance of common stock, net of issuance costs	34,437,364		—	64,907	—	—	64,907
Proceeds from sale of stock under employee stock purchase plan	93,362		—	78	—	—	78
Exercise of options	604,325		—	482	—	—	482
Stock-based compensation expense	—		—	2,187	—	—	2,187
Restricted stock unit vesting	1,660,547		—	—	—	—	—
Net income	—		—	—	—	6,112	6,112
Balance at March 31, 2025	261,644,590		$2	$1,696,821	$6	$(1,672,248)	$24,581
Issuance of common stock, net of issuance costs	850,000		—	1,542	—	—	1,542
Exercise of options	95,996		—	178	—	—	178
Stock-based compensation expense	—		—	2,676	—	—	2,676
Restricted stock unit vesting	451,246		—	—	—	—	—
Net income	—		—	—	—	247	247
Balance at June 30, 2025	263,041,832		$2	$1,701,217	$6	$(1,672,001)	$29,224
Warrants exercised, cashless	1,408,588		—	7,494	—	—	7,494
Proceeds from sale of stock under employee stock purchase plan	94,060		—	151	—	—	151
Exercise of options	438,300		—	962	—	—	962
Stock-based compensation expense	—		—	3,221	—	—	3,221
Restricted stock unit vesting	243,258		—	—	—	—	—
Net income	—		—	—	—	540	540
Balance at September 30, 2025	265,226,038		$2	$1,713,045	$6	$(1,671,461)	$41,592
Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Equity
(dollars in thousands)	Shares	Amount
Balance at December 31, 2025	265,424,818		$2	$1,716,307	$6	$(1,683,705)	$32,610
Proceeds from sale of stock under employee stock purchase plan	96,347		—	131	—	—	131
Exercise of options	28,424		—	20	—	—	20
Stock-based compensation expense	—		—	3,668	—	—	3,668
Restricted stock unit vesting	2,348,826		—	—	—	—	—
Net loss	—		—	—	—	(9,054)	(9,054)
Balance at March 31, 2026	267,898,415		$2	$1,720,126	$6	$(1,692,759)	$27,375
Issuance of common stock, net of issuance costs	3,138,107		—	3,240	—	—	3,240
Exercise of options	134,550		—	85	—	—	85
Stock-based compensation expense	—		—	3,226	—	—	3,226
Restricted stock unit vesting	571,645		—	—	—	—	—
Net loss	—		—	—	—	(8,908)	(8,908)
Balance at June 30, 2026	271,742,717		$2	$1,726,677	$6	$(1,701,667)	$25,018
Issuance of common stock, net of issuance costs	5,106,588		1	6,570	—	—	6,571
Proceeds from sale of stock under employee stock purchase plan	85,078		—	82	—	—	82
Exercise of options	400,519		—	251	—	—	251
Stock-based compensation expense	—		—	2,801	—	—	2,801
Restricted stock unit vesting	181,388		—	—	—	—	—
Net loss	—		—	—	—	(14,354)	(14,354)
Balance at September 30, 2026	277,516,290		$3	$1,736,381	$6	$(1,716,021)	$20,369

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.